Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)
Clinical trial NCT04389177 · UNKNOWN
Trial details
- NCT number
- NCT04389177
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-08
- Primary completion
- 2022-02-17
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.